Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.69
IRWD's Cash-to-Debt is ranked lower than
67% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. IRWD: 0.69 )
Ranked among companies with meaningful Cash-to-Debt only.
IRWD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.69  Med: 1.79 Max: 420.39
Current: 0.69
0.69
420.39
Equity-to-Asset 0.01
IRWD's Equity-to-Asset is ranked lower than
98% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. IRWD: 0.01 )
Ranked among companies with meaningful Equity-to-Asset only.
IRWD' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.86  Med: 0.26 Max: 0.74
Current: 0.01
-1.86
0.74
Debt-to-Equity 80.69
IRWD's Debt-to-Equity is ranked lower than
100% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. IRWD: 80.69 )
Ranked among companies with meaningful Debt-to-Equity only.
IRWD' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.02  Med: 1.1 Max: 80.69
Current: 80.69
-0.02
80.69
Debt-to-EBITDA -4.12
IRWD's Debt-to-EBITDA is ranked lower than
99.99% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. IRWD: -4.12 )
Ranked among companies with meaningful Debt-to-EBITDA only.
IRWD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -11.91  Med: -0.05 Max: -0.01
Current: -4.12
-11.91
-0.01
Piotroski F-Score: 4
Altman Z-Score: -0.23
Beneish M-Score: -1.38
WACC vs ROIC
11.04%
-91.45%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -42.58
IRWD's Operating Margin % is ranked lower than
82% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. IRWD: -42.58 )
Ranked among companies with meaningful Operating Margin % only.
IRWD' s Operating Margin % Range Over the Past 10 Years
Min: -1101.36  Med: -157.88 Max: -18.93
Current: -42.58
-1101.36
-18.93
Net Margin % -52.97
IRWD's Net Margin % is ranked lower than
84% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. IRWD: -52.97 )
Ranked among companies with meaningful Net Margin % only.
IRWD' s Net Margin % Range Over the Past 10 Years
Min: -1192.31  Med: -164.11 Max: -29.83
Current: -52.97
-1192.31
-29.83
ROE % -296.28
IRWD's ROE % is ranked lower than
97% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. IRWD: -296.28 )
Ranked among companies with meaningful ROE % only.
IRWD' s ROE % Range Over the Past 10 Years
Min: -299.34  Med: -128.16 Max: -48.14
Current: -296.28
-299.34
-48.14
ROA % -20.21
IRWD's ROA % is ranked lower than
81% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. IRWD: -20.21 )
Ranked among companies with meaningful ROA % only.
IRWD' s ROA % Range Over the Past 10 Years
Min: -107.22  Med: -35.95 Max: -12.3
Current: -20.21
-107.22
-12.3
ROC (Joel Greenblatt) % -523.34
IRWD's ROC (Joel Greenblatt) % is ranked lower than
90% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. IRWD: -523.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IRWD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1275.86  Med: -306.95 Max: -159
Current: -523.34
-1275.86
-159
3-Year Revenue Growth Rate 112.10
IRWD's 3-Year Revenue Growth Rate is ranked higher than
98% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. IRWD: 112.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
IRWD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -9.3 Max: 112.1
Current: 112.1
0
112.1
3-Year EBITDA Growth Rate -52.90
IRWD's 3-Year EBITDA Growth Rate is ranked lower than
99% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. IRWD: -52.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
IRWD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -7.6 Max: 51.9
Current: -52.9
0
51.9
3-Year EPS without NRI Growth Rate -38.00
IRWD's 3-Year EPS without NRI Growth Rate is ranked lower than
92% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. IRWD: -38.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
IRWD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -38 Max: 54.1
Current: -38
0
54.1
GuruFocus has detected 2 Warning Signs with Ironwood Pharmaceuticals Inc $IRWD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IRWD's 30-Y Financials

Financials (Next Earnings Date: 2017-11-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

IRWD Guru Trades in Q3 2016

Joel Greenblatt 147,976 sh (+10.58%)
Vanguard Health Care Fund 4,522,387 sh (unchged)
Ken Fisher 242,450 sh (unchged)
Paul Tudor Jones 30,489 sh (-10.64%)
Steven Cohen 953,927 sh (-18.27%)
» More
Q4 2016

IRWD Guru Trades in Q4 2016

Vanguard Health Care Fund 4,533,887 sh (+0.25%)
Paul Tudor Jones 28,674 sh (-5.95%)
Joel Greenblatt 131,163 sh (-11.36%)
Ken Fisher 202,850 sh (-16.33%)
Steven Cohen 291,532 sh (-69.44%)
» More
Q1 2017

IRWD Guru Trades in Q1 2017

Jim Simons 186,453 sh (New)
Steven Cohen 1,628,018 sh (+458.44%)
Joel Greenblatt 363,051 sh (+176.79%)
Vanguard Health Care Fund 4,586,087 sh (+1.15%)
Ken Fisher 202,850 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2017

IRWD Guru Trades in Q2 2017

Jim Simons 630,253 sh (+238.02%)
Vanguard Health Care Fund 4,586,087 sh (unchged)
Ken Fisher 202,850 sh (unchged)
Steven Cohen 844,400 sh (-48.13%)
Joel Greenblatt 176,954 sh (-51.26%)
» More
» Details

Insider Trades

Latest Guru Trades with IRWD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-06-30 Reduce -51.26%0.04%$15.48 - $19.61 $ 15.45-11%176,954
Vanguard Health Care Fund 2017-03-31 Add 1.15%$13.95 - $18 $ 15.45-5%4,586,087
Joel Greenblatt 2017-03-31 Add 176.79%0.05%$13.95 - $18 $ 15.45-5%363,051
Vanguard Health Care Fund 2016-12-31 Add 0.25%$12.66 - $16.76 $ 15.452%4,533,887
Ken Fisher 2016-12-31 Reduce -16.33%$12.66 - $16.76 $ 15.452%202,850
Joel Greenblatt 2016-12-31 Reduce -11.36%$12.66 - $16.76 $ 15.452%131,163
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:SZSE:300601, TSE:4540, SZSE:300199, SHSE:600380, TSE:4527, SZSE:000078, SZSE:002390, BOM:532296, NAS:MDCO, TSE:4555, TSE:4521, XLJU:KRKG, SHSE:603567, SHSE:600062, NAS:HZNP, NAS:ENDP, NAS:SUPN, SZSE:002038, SHSE:600277, SHSE:600267 » details
Traded in other countries:I76.Germany,
Headquarter Location:USA
Ironwood Pharmaceuticals Inc is a biotechnology company which is focused on advancing innovative product opportunities in areas of large unmet needs such as constipation, gastrointestinal disorders, hyperuricemia, among others.

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Top Ranked Articles about Ironwood Pharmaceuticals Inc

What Do the Ardelyx Numbers Mean for the Company? Here's a look at the latest Ardelyx data
Ardelyx Inc. (NASDAQ:ARDX) just put out data from a phase III study of its lead development asset – tenapanor. The study was the first of two planned phase IIIs with the combined data from each expected to underpin a registration submission with the Food and Drug Administration (FDA) on completion. Read more...
Allergan and Ironwood Launch Campaign Designed to Empower the Nearly 64 Million Americans Estimated to Suffer from IBS and CIC to Talk About Bowel Health(1-5)

Ratios

vs
industry
vs
history
PB Ratio 468.18
IRWD's PB Ratio is ranked lower than
100% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. IRWD: 468.18 )
Ranked among companies with meaningful PB Ratio only.
IRWD' s PB Ratio Range Over the Past 10 Years
Min: 5.45  Med: 13.6 Max: 593.33
Current: 468.18
5.45
593.33
PS Ratio 8.38
IRWD's PS Ratio is ranked lower than
78% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. IRWD: 8.38 )
Ranked among companies with meaningful PS Ratio only.
IRWD' s PS Ratio Range Over the Past 10 Years
Min: 3.5  Med: 15.17 Max: 75.81
Current: 8.38
3.5
75.81
EV-to-EBIT -22.95
IRWD's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. IRWD: -22.95 )
Ranked among companies with meaningful EV-to-EBIT only.
IRWD' s EV-to-EBIT Range Over the Past 10 Years
Min: -60.5  Med: -13.6 Max: -4.2
Current: -22.95
-60.5
-4.2
EV-to-EBITDA -25.47
IRWD's EV-to-EBITDA is ranked lower than
99.99% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. IRWD: -25.47 )
Ranked among companies with meaningful EV-to-EBITDA only.
IRWD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -88.3  Med: -15.15 Max: -4.4
Current: -25.47
-88.3
-4.4
EV-to-Revenue 8.97
IRWD's EV-to-Revenue is ranked lower than
78% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. IRWD: 8.97 )
Ranked among companies with meaningful EV-to-Revenue only.
IRWD' s EV-to-Revenue Range Over the Past 10 Years
Min: 6.4  Med: 16.1 Max: 78.6
Current: 8.97
6.4
78.6
Current Ratio 4.27
IRWD's Current Ratio is ranked higher than
72% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. IRWD: 4.27 )
Ranked among companies with meaningful Current Ratio only.
IRWD' s Current Ratio Range Over the Past 10 Years
Min: 2.33  Med: 4.41 Max: 9.64
Current: 4.27
2.33
9.64
Quick Ratio 4.27
IRWD's Quick Ratio is ranked higher than
76% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. IRWD: 4.27 )
Ranked among companies with meaningful Quick Ratio only.
IRWD' s Quick Ratio Range Over the Past 10 Years
Min: 2.33  Med: 4.3 Max: 9.04
Current: 4.27
2.33
9.04
Days Inventory 30.18
IRWD's Days Inventory is ranked higher than
92% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. IRWD: 30.18 )
Ranked among companies with meaningful Days Inventory only.
IRWD' s Days Inventory Range Over the Past 10 Years
Min: 30.18  Med: 193.31 Max: 1266.91
Current: 30.18
30.18
1266.91
Days Sales Outstanding 5.36
IRWD's Days Sales Outstanding is ranked higher than
96% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. IRWD: 5.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
IRWD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.05  Med: 7.61 Max: 889.76
Current: 5.36
0.05
889.76
Days Payable 1.00
IRWD's Days Payable is ranked lower than
99% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.69 vs. IRWD: 1.00 )
Ranked among companies with meaningful Days Payable only.
IRWD' s Days Payable Range Over the Past 10 Years
Min: 1  Med: 513.78 Max: 8217.61
Current: 1
1
8217.61

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.70
IRWD's 3-Year Average Share Buyback Ratio is ranked lower than
57% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. IRWD: -6.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IRWD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -144.5  Med: -9.9 Max: 0
Current: -6.7
-144.5
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.55
IRWD's Price-to-Median-PS-Value is ranked higher than
88% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. IRWD: 0.55 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IRWD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.27  Med: 1.1 Max: 4.12
Current: 0.55
0.27
4.12
Earnings Yield (Greenblatt) % -4.36
IRWD's Earnings Yield (Greenblatt) % is ranked lower than
77% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. IRWD: -4.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IRWD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -23.6  Med: -7.3 Max: -1.7
Current: -4.36
-23.6
-1.7

More Statistics

Revenue (TTM) (Mil) $270.81
EPS (TTM) $ -0.98
Beta1.47
Short Percentage of Float21.56%
52-Week Range $12.48 - 19.94
Shares Outstanding (Mil)149.59

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 292 434 492 581
EPS ($) -0.85 -0.05 0.39 0.83
EPS without NRI ($) -0.85 -0.05 0.39 0.83
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}